$1.30
+0.05 (+4.00%)
Open$1.24
Previous Close$1.25
Day High$1.30
Day Low$1.21
52W High$11,679.60
52W Low—
Volume—
Avg Volume229.0K
Market Cap647.3K
P/E Ratio—
EPS$-13,217.70
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+938.5% upside
Current
$1.30
$1.30
Target
$13.50
$13.50
$9.80
$13.50 avg
$19.20
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 578.23M | 541.41M | 180.5K |
| Net Income | -148,652,679,361 | -125,269,111,821 | -19,611 |
| Profit Margin | -25,708.3% | -24,422.8% | -10.9% |
| EBITDA | -118,496,025,710 | -105,403,768,187 | -25,362 |
| Free Cash Flow | — | — | -13,693 |
| Rev Growth | +6.8% | +6.8% | +10.1% |
| Debt/Equity | 0.65 | 0.65 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |